Grove Biopharma, Inc. | $30,000,000 | (Apr 25, 2025)
Northwood | $30,000,000 | (Apr 25, 2025)
Steadily Insurance Company | $30,000,000 | (Apr 25, 2025)
Certified by Founder
Lodge
Merida Biosciences
start up
- 10/04/2025
- Series A
- $121,000,000
Merida Biosciences is a biotechnology company pioneering a new class of precision therapeutics designed to selectively and durably eliminate pathogenic antibodies that drive disease. The company is advancing a robust pipeline to precisely eliminate the root cause of multiple autoimmune and allergic conditions that are inadequately treated today. Its lead program is designed to specifically and rapidly clear the pathogenic autoantibodies that cause Graves' disease, an autoimmune disorder that affects the thyroid gland. Merida was publicly launched in April 2025 and is based in Cambridge, MA. For more information about Merida, visit www.meridabio.com.
- Industry Biotechnology Research
- Website https://meridabio.com/
- LinkedIn https://www.linkedin.com/company/merida-biosciences/
Alternative Payments | $22,000,000 | (Apr 25, 2025)
Listen Labs | $27,000,000 | (Apr 25, 2025)
Lace | $14,000,000 | (Apr 25, 2025)
RISE® Robotics | $1,500,000 | (Apr 25, 2025)
Ravenna | $15,000,000 | (Apr 25, 2025)
ChEmpower Corporation | $18,700,000 | (Apr 25, 2025)
Theo | $20,000,000 | (Apr 25, 2025)
Isembard | $9,000,000 | (Apr 25, 2025)
Electra(US) | $186,000,000 | (Apr 25, 2025)